Replies to post #129594 on Biotech Values

[biomaven0]

From VRTX just released abstract - deaths are always worrying, and TB being of concern as well:

Adverse events (AE) led to discontinuation in 7.9% of VX-509 subjects and 4.8% of placebo subjects. Infections were the most common AE, occurring with similar frequency in placebo (17%) and VX-509 subjects (12-25%). Serious AEs occurred in 4.9% of VX-509 and 2.4% of placebo subjects, with serious infection in 3.1% of VX-509 subjects (100 mg, n=3; 150 mg, n=2, including 1 case of TB) and none in placebo. Two deaths occurred in the VX-509 group (100 mg): 1 subarachnoid hemorrhage, 1 pneumonia. AEs of transaminase elevations were seen in 5.5% of VX-509 subjects and 4.9% of placebo subjects.